Salvarani C, Pipitone N, Versari A, Hunder GG (2012) Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8(9):509–521. https://doi.org/10.1038/nrrheum.2012.97

Article  CAS  PubMed  Google Scholar 

Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 56(4):506–515. https://doi.org/10.1093/rheumatology/kew273

Article  CAS  PubMed  Google Scholar 

Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, Pipitone N, Catanoso MG, Boiardi L (2005) Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53(2):293–297. https://doi.org/10.1002/art.21075

Article  PubMed  Google Scholar 

Buttgereit F, Dejaco C, Matteson EL, Dasgupta B (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315(22):2442–2458. https://doi.org/10.1001/jama.2016.5444

Article  CAS  PubMed  Google Scholar 

Matteson EL, Buttgereit F, Dejaco C, Dasgupta B (2016) Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin N Am 42(1):75–90. https://doi.org/10.1016/j.rdc.2015.08.009

Article  Google Scholar 

Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, Espigol-Frigole G, Butjosa M, Hernandez-Rodriguez J, Cid MC (2014) Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 93(5):194–201. https://doi.org/10.1097/MD.0000000000000033

Article  PubMed  Google Scholar 

Labarca C, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Matteson EL, Warrington KJ (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55(2):347–356. https://doi.org/10.1093/rheumatology/kev348

Article  PubMed  Google Scholar 

Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA (2021) 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and takayasu arteritis. Arthritis Care Res (Hoboken) 73(8):1071–1087. https://doi.org/10.1002/acr.24632

Article  PubMed  Google Scholar 

Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19–30. https://doi.org/10.1136/annrheumdis-2019-215672

Article  PubMed  Google Scholar 

Tsalapaki C, Nikitopoulou E, Boki KA, Boumpas D, Sfikakis PP, Vosvotekas G, Voulgari PV, Vassilopoulos D (2018) Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. Mediterr J Rheumatol 29(2):103–105. https://doi.org/10.31138/mjr.29.2.103

Article  PubMed  PubMed Central  Google Scholar 

Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128. https://doi.org/10.1002/art.1780330810

Article  CAS  Google Scholar 

Perrineau S, Ghesquière T, Charles P, Paule R, Samson M, Gayraud M, Chauvin A, Terrier B, Guillevin L, Bonnotte B, Mouthon L, Régent A (2021) A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. Clin Exp Rheumatol 39(2):155–160. https://doi.org/10.55563/clinexprheumatol/0nd4kk

Article  PubMed  Google Scholar 

Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A (2018) Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int 38(4):569–577. https://doi.org/10.1007/s00296-017-3874-3

Article  CAS  PubMed  Google Scholar 

Restuccia G, Boiardi L, Cavazza A, Catanoso M, Macchioni P, Muratore F, Cimino L, Aldigeri R, Crescentini F, Pipitone N, Salvarani C (2016) Flares in biopsy-proven giant cell arteritis in Northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore) 95(19):e3524. https://doi.org/10.1097/MD.0000000000003524

Article  PubMed  Google Scholar 

Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH (2021) Treatment failure in giant cell arteritis. Ann Rheum Dis 80(11):1467–1474. https://doi.org/10.1136/annrheumdis-2021-220347

Article  CAS  PubMed  Google Scholar 

Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M, Napalkov P, Jick SS, Stone JH, Meier CR (2017) Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum 46(6):819–827. https://doi.org/10.1016/j.semarthrit.2016.11.006

Article  CAS  PubMed  Google Scholar 

Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N (2015) Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken) 67(3):390–395. https://doi.org/10.1002/acr.22429

Article  CAS  PubMed  Google Scholar 

Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49(5):703–708. https://doi.org/10.1002/art.11388

Article  CAS  PubMed  Google Scholar 

Martinez-Lado L, Calvino-Diaz C, Pineiro A, Dierssen T, Vazquez-Rodriguez TR, Miranda-Filloy JA, Lopez-Diaz MJ, Blanco R, Llorca J, Gonzalez-Gay MA (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90(3):186–193. https://doi.org/10.1097/MD.0b013e31821c4fad

Article  PubMed  Google Scholar 

Mainbourg S, Addario A, Samson M, Puechal X, Francois M, Durupt S, Gueyffier F, Cucherat M, Durieu I, Reynaud Q, Lega JC (2020) Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res (Hoboken) 72(6):838–849. https://doi.org/10.1002/acr.23901

Article  CAS  PubMed  Google Scholar 

Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Maksimowicz-McKinnon K, McAlear CA, Monach PA, Seo P, Merkel PA, Ytterberg SR (2015) Disease relapses among patients with giant cell arteritis: a prospective longitudinal cohort study. J Rheumatol 42(7):1213–1217. https://doi.org/10.3899/jrheum.141347

Article  PubMed  PubMed Central  Google Scholar 

Dumont A, Parienti JJ, Delmas C, Boutemy J, Maigne G, Martin Silva N, Sultan A, Planchard G, Aouba A, de Boysson H (2020) Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol 47(1):108–116. https://doi.org/10.3899/jrheum.181127

Article  CAS  PubMed  Google Scholar 

Hernández-Rodríguez J, García-Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, Fernández-Solà J, Urbano-Márquez A, Grau JM, Cid MC (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47(1):29–35. https://doi.org/10.1002/art1.10161

Article  CAS  PubMed  Google Scholar 

García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, Prieto-González S, Butjosa M, Segarra M, Lozano E, Cid MC (2010) Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 62(6):835–841. https://doi.org/10.1002/acr.20043

Article  CAS  PubMed  Google Scholar 

Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M (2020) Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther 22(1):72. https://doi.org/10.1186/s13075-020-02171-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Espitia O, Néel A, Leux C, Connault J, Espitia-Thibault A, Ponge T, Dupas B, Barrier JH, Hamidou MA, Agard C (2012) Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup. J Rheumatol 39(11):2157–2162. https://doi.org/10.3899/jrheum.120511

Article  PubMed  Google Scholar 

Ray JG, Mamdani MM, Geerts WH (2005) Giant cell arteritis and cardiovascular disease in older adults. Heart 91(3):324–328. https://doi.org/10.1136/hrt.2004.037481

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arias M, Heydari-Kamjani M, Kesselman MM (2021) Giant cell arteritis and cardiac comorbidity. Cureus 13(2):e13391. https://doi.org/10.7759/cureus.13391

Article  PubMed  PubMed Central  Google Scholar